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ABSTRACT
Objectives Sickle cell disease (SCD) leads to chronic 
and acute complications that require specialised care 
to manage symptoms and optimise clinical results. The 
National Heart Lung and Blood Institute (NHLBI) evidence- 
based guidelines assist providers in caring for individuals 
with SCD, but adoption of these guidelines by providers 
has not been optimal. The objective of this study was to 
identify barriers to treating individuals with SCD.
Methods The SCD Implementation Consortium aimed to 
investigate the perception and level of comfort of providers 
regarding evidence- based care by surveying providers in 
the regions of six clinical centres across the USA, focusing 
on non- emergency care from the providers’ perspective.
Results Respondents included 105 providers delivering 
clinical care for individuals with SCD. Areas of practice 
were most frequently paediatrics (24%) or haematology/
SCD specialist (24%). The majority (77%) reported that 
they were comfortable managing acute pain episodes 
while 63% expressed comfort with managing chronic 
pain. Haematologists and SCD specialists showed 
higher comfort levels prescribing opioids (100% vs 67%, 
p=0.004) and managing care with hydroxyurea (90% 
vs 51%, p=0.005) compared with non- haematology 
providers. Approximately 33% of providers were unaware 
of the 2014 NHLBI guidelines. Nearly 63% of providers felt 
patients’ medical needs were addressed while only 22% 
felt their mental health needs were met.
Conclusions A substantial number of providers did 
not know about NHLBI’s SCD care guidelines. Barriers 
to providing care for patients with SCD were influenced 
by providers’ specialty, training and practice setting. 
Increasing provider knowledge could improve hydroxyurea 
utilisation, pain management and mental health support.
INTRODUCTION
Sickle cell disease (SCD) is a genetic, multi-
system disorder with chronic and acute 
complications.1 End- organ damage is cumula-
tive and leads to organ dysfunction (eg, renal 
insufficiency or joint damage) as patients 
age.1 2 Acute events (eg, vaso- occlusive pain 
and acute chest syndrome) are often unpre-
dictable and lead to frequent acute care 
visits.3 The complexity of SCD requires 
specialised, multidisciplinary care to mitigate 
disease complications and promote optimal 
clinical results. In the USA, SCD primarily 
affects people of colour who are often socio-
economically disadvantaged; therefore, clin-
ical management requires not only specific 
medical expertise but cultural responsiveness 
from the providers.4 5
In 2014, the National Heart Lung 
and Blood Institute (NHLBI) published 
evidence- based guidelines to assist providers 
in caring for individuals with SCD.6 The 
guidelines appear not to be widely adopted in 
practice,7–9 which poses an important oppor-
tunity to improve care delivery for persons 
living with SCD. Barriers to guideline- based 
care include healthcare provider unpre-
paredness, lack of knowledge and stigma 
related to pain episodes and pain medica-
tion.10–12 Across the USA, providers caring 
Strengths and limitations of this study
 ► The Sickle Cell Disease Implementation Consortium 
surveyed providers in the regions of six clinical cen-
tres across the USA, focusing on non- emergency 
care from the providers’ perspective.
 ► The providers were selected by convenience sam-
pling and may not be representative of all SCD care 
in the USA, however, respondents were included 
from diverse regions.
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for persons with SCD have a wide range of training and 
expertise, potentially leading to large discrepancies in 
provider knowledge and preparedness. Additionally, 
there is evidence that some bias and negative percep-
tions toward the SCD population exists among medical 
professionals, negatively affecting the quality of care 
received by patients.13 14
Discrepancies in provider knowledge and preparedness 
towards individuals with SCD likely impact care across 
specialties and settings but are not fully understood. 
This may affect multiple aspects of evidence- based sickle 
cell care, such as prescribing of opioids, prescribing the 
disease modifier hydroxyurea, treating acute pain or 
treating chronic complications of the disease. A more 
comprehensive understanding of provider perceptions 
and level of comfort caring for SCD is needed.
To address this research gap, the SCD Implementation 
Consortium (SCDIC) surveyed potential care providers 
for individuals with SCD, to identify likely modifiable 
barriers to optimal care for patients with SCD across 
the USA, with the ultimate goal of fostering adoption 
of national guidelines for SCD care. The SCDIC previ-
ously reported results from a separate survey to assess 
barriers to care within emergency departments (EDs) 
that did not include non- ED providers.15 In this explor-
atory study, we surveyed a wide range of providers from 
different regions of the country and in different areas of 
medicine, focusing on non- emergency care and assessing 
the perceptions and factors that influenced their level of 
comfort in prescribing opioids and hydroxyurea as well 
as their knowledge and perceptions of managing compli-
cations of the disease. Our goal was to identify barriers 
in treating patients with SCD, with a specific focus on 
hydroxyurea and opioid prescriptions, and to inform 
the development of specific intervention strategies to be 
employed in planned implementation science studies 
within the SCDIC.
METHODS
The SCDIC includes eight clinical centres across the USA, 
funded by NHLBI and coordinated through Research 
Triangle Institute International. The goal of the SCDIC is 
to improve care for patients with SCD by assessing current 
needs and implementing multilevel interventions. 
Consortium details have been previously described.16 
Six of the eight sites from the consortium contributed to 
the provider needs assessment survey and the summary 
results are detailed in this report.
Study design
SCDIC investigators conducted an anonymous multisite, 
cross- sectional survey of healthcare providers. In this 
purposive sample, each SCDIC site offered the survey to 
multiple clinics and healthcare providers in their region 
through email, phone or in- person administration.
Patient and public involvement
The SCDIC includes a diverse, multidisciplinary group 
of clinicians, scientists, patients and patient advocates.16 
All SCDIC members provided guidance and feedback 
for consortium projects. Results from this needs assess-
ment were shared with the entire group, to inform future 
consortium initiatives.
Provider recruitment and procedures
Participants were eligible if they were healthcare profes-
sionals who practised at any type of healthcare facility in 
the same region as one of the six participating SCDIC sites 
(listed in the ethics section below). A multimodal recruit-
ment strategy was used, recruiting participants through 
mail invitation, email invitation (online survey) and a 
face- to- face approach. Methods for identifying eligible 
providers included assessing Continuing Medical Educa-
tion (CME) databases, board certification databases, 
medical professional organisations, the California SCD 
surveillance project, practices known to investigators, 
and professional networks. The current analysis includes 
all respondents who reported that they cared for patients 
with SCD. Due to the multimodal recruitment strategy, 
it was not feasible to track the total number of providers 
approached to take the survey, and no response rate can 
be calculated. Participants completed the survey online 
with responses recorded directly in a Research Electronic 
Data Capture17 database; responses were anonymous. 
Expected time to complete the survey was 10 min.
Measures/survey elements
A 44- question survey was designed by the SCDIC needs 
assessment committee and included four primary 
domains: (1) Provider Demographics, (2) Experiences 
and comfort providing care to patients with SCD, (3) CME 
in SCD, (4) Open- ended comments about the care and 
management of patients with SCD (online supplemental 
files 12). The survey consisted of sets of items compiled 
from existing provider surveys.11 18 19 Providers indicated 
their level of experience with caring for patients with SCD; 
care provided, such as routine screening; and comfort 
level with providing preventive care, managing comor-
bidities, and managing acute and chronic pain. Providers 
were asked what potential facilitators might improve care 
for patients with SCD, including higher reimbursement, 
case management services, access to pain management 
specialists and access to clinical decision support tools. 
Providers rated a list of 16 barriers to using opioids on a 
five- point scale from ‘not a barrier’ to ‘complete barrier’. 
Providers responded to specific questions about manage-
ment with hydroxyurea (eg, criteria for, barriers to and 
comfort level with prescribing).8 Questions were evalu-
ated individually without scaling or creating composite 
measures.
Statistical analysis
Analyses included descriptive and comparative statistics. 
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percentages overall and by groups; subjects with missing 
values were excluded from percentage calculation. Asso-
ciations were evaluated with χ2 tests or, when appropriate, 
Fisher’s exact test. Two- sided p<0.05 was considered 
indicative of statistical significance. All provider demo-
graphics (including age, race, and gender of provider, 
provider type, area of practice, practice setting, number 
of years in clinical practice and age range of patients) 
were compared with responses to questions about expe-
rience and comfort providing care to patients with SCD 
as well as their experience with and perception of opioid 
and hydroxyurea treatments. No adjustment for multiple 
comparisons were done due to the exploratory nature of 
this analysis.20 Analyses were conducted in SAS V.9.4.
RESULTS
Demographics
A total of 105 providers who cared for patients with SCD 
responded to the survey. Respondents were 53% female, 
65% white and most (37%) were between 31 and 50 
years of age (table 1). Seventy- one percent of the respon-
dents were physicians, 18% nurse practitioners or physi-
cian’s assistants and 4% registered nurses (table 1). The 
providers’ primary areas of practice were most frequently 
paediatrics (24%), or haematology/SCD- specialty (24%). 
Respondents most frequently reported practising in 
an urban setting (83%), followed by rural (10%) and 
suburban (8%) (table 1).
Comfort level with pain management and opioid prescriptions
The majority (76%) of the providers reported that they 
were either ‘somewhat comfortable’ or ‘very comfort-
able’ with their ability to manage acute pain episodes 
experienced by patients with SCD (table 2). A smaller 
proportion (63%) reported they were either ‘somewhat 
comfortable’ or ‘very comfortable’ managing chronic 
pain (table 2).
Approximately 74% of providers reported prescribing 
opioids to patients with SCD (table 2). The most 
commonly reported barriers (rated as ‘moderate’ or 
‘complete’) to prescribing opioids to patients with SCD 
were drug dependence (63%), tolerance (60%) and 
addiction (54%) (figure 1, online supplemental file 
2). No statistically significant associations were found 
between providers’ characteristics and comfort with 
managing acute pain.
Prescribing opioids for SCD pain was also associated 
with providers’ area of practice with haematologists and 
SCD specialists more likely to prescribe opioids than 
those of different specialties (p=0.004, table 3). Barriers 
to prescribing opioids were explored for potential differ-
ences by practice specialty, area of practice, provider type 
and years in clinical practice. The only significant asso-
ciation found suggested that providers from rural areas 
may have more moderate or complete regulatory barriers 
(4/6 (66.7%)) compared with those in urban settings 
(11/49 (29%)) (p=0.0213).
Table 1 Provider demographics and practice 





  18–30 years 9 (8.6)
  31–50 years 39 (37.1)
  51–70 years 22 (21.0)
  Don’t know/prefer not to respond 35 (33.3)
Sex
  Male 39 (45.2)
  Female 33 (53.4)
  Don’t know/prefer not to respond 1 (1.4)
  (32 missing)
Race
  American Indian or Alaskan native 2 (2.6)
  Asian 9 (11.5)
  Black or African American 8 (10.3)
  Native Hawaiian or Other Pacific Islander 0 (0)
  White 51 (65.4)
  Other 1 (1.3)
  Don’t know/prefer not to respond 7 (9.0)
  (27 missing)
Years in practice
  <1 year 2 (2.6)
  1–5 years 25 (32.9)
  6–10 years 13 (17.1)
  11–20 years 15 (19.7)
  21–30 years 14 (18.4)
  31–40 years 5 (6.6)
  41–50 years 0 (0.0)
  Don’t know/prefer not to respond 2 (2.6)
  (29 missing)
Provider licensure
  Medical doctor 55 (71.4)
  Nurse practitioner 11 (14.3)
  Physician’s assistant 3 (3.9)
  Registered nurse 3 (3.9)
  Other 5 (6.5)
  (28 Missing)
Primary area of practice
  Family medicine 15 (19.2)
  Haematology/SCD specific 19 (24.4)
  Internal medicine 8 (10.3)
  Paediatrics 19 (24.4)
  Other/prefer not to provide 17 (21.8)
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Comfort level in prescribing hydroxyurea
Nearly 85% of providers indicated that they managed 
hydroxyurea therapy for their patients with SCD with 35% 
of them managing it for more than half of their patients. 
The most common criteria for placing patients on hydroxy-
urea therapy included episodes of acute chest syndrome 
(43%), at least three painful episodes per year requiring 
hospitalisation (42%), at least three painful episodes per 
year at home (31%), chronic pain requiring excessive or 
frequent opioid use (35%) or a history of stroke (31%) 
(online supplemental file 2). Providers’ frequently 
reported that their decision to prescribe hydroxyurea was 
influenced by patient anticipation of side effects, concerns 
for infertility in male patients and patient/family adher-
ence with hydroxyurea (figure 2, online supplemental file 
2). Additionally, 59% of providers reported some level of 
discomfort prescribing hydroxyurea based on a perceived 
carcinogenesis potential. Providers’ comfort level in 
managing hydroxyurea for patients with SCD was signifi-
cantly associated with their practice specialty, with 90% 
of haematology or SCD providers reporting they were 
‘somewhat’ or ‘very comfortable’, compared with 51% 
other providers (p=0.0049, table 3).
Physician resources and perception on patients needs
Over half of all respondents reported providing primary 
care for at least 10 patients with SCD in the past year 
(53%) (online supplemental file 2). Additionally, over 
half of the providers reported using resources such as the 
internet (60%), a colleague (57%) or a specialist (71%) 
when seeking information about the management of 
patients with SCD. Only 63% reported that they felt the 
medical needs of their patients with SCD were addressed 
and merely 22% felt that the behavioural or mental health 
needs of their patients with SCD were being met. No 
significant associations between provider demographics 
were found for physician resources or perception of 
patient needs.
Tools for SCD care
About 33% of the providers were unaware of the SCD 
Evidence- Based Guidelines published by the NHLBI 
(online supplemental file 2). Over half of the providers 
reported that a clinical decision support tool for SCD 
would be ‘useful’ or ‘very useful’ for diagnosis, treat-
ment and preventing complications (50%, 74% and 75% 




  Rural 6 (9.5)
  Urban 52 (82.5)
  Suburban 5 (7.9)
  (42 missing)
Age of the patients with SCD cared for
  Infancy through young adult 55 (59.1)
  Adults (ages ≥18 years) 38 (40.9)
  (12 missing)
SCD, sickle cell disease.
Table 1 Continued
Table 2 Comfort level with pain management in sickle 
cell disease (N=105); Sickle Cell Disease Implementation 
Consortium, USA, 2021
Frequency n (%)
Managing acute pain episodes
  Very uncomfortable 9 (9.2)
  Somewhat uncomfortable 10 (10.2)
  Neither comfortable or uncomfortable 3 (3.1)
  Somewhat comfortable 30 (30.6)
  Very comfortable 45 (45.9)
  Don’t know/prefer not to respond 1 (1.0)
  (7 missing)
Managing chronic pain
  Very uncomfortable 7 (7.4)
  Somewhat uncomfortable 20 (21.3)
  Neither comfortable or uncomfortable 5 (5.3)
  Somewhat comfortable 44 (46.8)
  Very comfortable 15 (16.0)
  Don’t know/prefer not to respond 3 (3.2)
  (11 missing)
Prescribe opioids
  Yes 73 (73.7)
  No 23 (23.2)
  Don’t know/prefer not to respond 3 (3.0)
  (6 missing)

















Barriers to prescribing opioids for SCD chronic pain 
Not a barrier Minimal barrier Somewhat a barrier Moderate barrier Complete barrier
*prior authorization, dose adjustment, and state database assessment
Figure 1 Barriers to prescribing opioids: the extent of 
providers caring for persons with SCD who report each 
reason as a moderate or complete barrier to opioid 
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significant provider demographic associations with tools, 
guidelines or barriers to prescribing hydroxyurea.
DISCUSSION
Although there are evidence- based guidelines for patients 
with SCD in the USA, they have not been fully adopted in 
practice.10 21 Providers’ perspectives on not fully adopting 
national SCD guidelines of care have not been systemat-
ically investigated and constitute important barriers to 
delivery of quality care. In this study, we surveyed physi-
cians, advanced practice providers, psychologists and 
registered nurses from a variety of non- acute practice 
settings to better understand their perceptions toward 
barriers to care in SCD and non- adoption of national SCD 
guidelines. Our findings showed that providers who were 
not haematologists or SCD specialists were less comfort-
able prescribing hydroxyurea and cited concerns about 
side effects and patient adherence as potential barriers. 
Most providers felt comfortable managing pain in patients 
with SCD but reported substantial barriers to prescribing 
opioids. Additionally, providers of patients with SCD 
reported that the medical needs of the patients are not 
being sufficiently met and an overwhelming majority of 
them reported that the behavioural and mental health 
needs of patients with SCD are not being met.
The setting and type of practitioner were associated 
with the frequency of and barriers to prescribing opioids. 
Haematologists or SCD specialists more frequently 
prescribed opioids for patients with SCD and providers 
in urban settings cited fewer barriers. Frequently cited 
barriers to opioid use were addiction, dependence and 
tolerance. These barriers may be exacerbated by the 
current opioid crisis and related measures to restrict 
opioid use in the USA, which continues to receive national 
attention.22 However, it has been shown that addiction to 
opioids is not more common in SCD than the general 
population, despite higher opioid utilisation.23 Uncon-
scious bias among physicians has been shown to be a 
factor that negatively impacts persons with SCD.13 Results 
from an SCDIC survey of ED physicians found similar 
barriers to opioid use in patients with SCD including the 
opioid epidemic, addiction and implicit bias.15 Addition-
ally, the authors found that, although ED physicians felt 
very comfortable in their knowledge of caring for patients 
with SCD, 75% were unaware of NHLBI care recommen-
dations for patients with SCD and vaso- occlusive crisis.15 
In both non- emergency and emergency settings, these 
factors, coupled with suboptimal awareness of SCD care 
guidelines, create great dissatisfaction with care among 
patients,24 and suggest the need for more SCD specific 
training for physicians. Many of the providers in this 
survey were relatively early in their career or cared for 
fewer than 10 patients with SCD per year. Training should 
be developed specifically to target physicians who are not 
haematologists or SCD specialists, who likely see lower 
numbers of persons with SCD. This training could also 
be integrated into training programmes for general 
practitioners.
Nearly 80% of providers surveyed felt the mental health 
needs of patients with SCD were not met, highlighting an 
important gap in care. Mental health has an important 
impact on health- related quality of life (HRQOL)25 and 
influences pain management for persons with SCD.26 
Furthermore, worse HRQOL has been associated with 
Table 3 Associations between provider area of practice and opioid and hydroxyurea utilisation; Sickle Cell Disease (SCD) 
Implementation Consortium, USA, 2021
Main area of practice
Haematology/SCD Other P value*
Prescribe opioids to patients with SCD
  No 0 (0) 18 (32.7) 0.004
  Yes 17 (100) 37 (67.3)
Comfortable managing hydroxyurea therapy for SCD
  Neutral, somewhat or very uncomfortable 2 (10.5) 25 (49.0) 0.0049
  Somewhat or very comfortable 17 (89.5) 26 (51.0)
*Fisher’s exact test.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Cost Issues
Patients’ lack of contraception/possible pregnancy
Doubt the effectiveness of the drug
Age of patient (patient is too young)
Discomfort with carcinogenesis potential
Patient/family adherence with required blood tests
Hydroxyurea is not FDA approved for use in children*
There is a lack of formal guidelines for use in children
Time/resources to adequately explain risks/benefits
Concerns of infertility in male patients
Patient/family adherence with hydroxyurea
Patient anticipation of side effects
Barriers to Prescribing of Hydroxyurea
Don't know Not important Somewhat important Important Very important
*At the time of survey administration, Hydroxyurea had not been FDA-approved in children
Figure 2 Barriers to prescribing hydroxyurea: the 
importance of barriers providers face to prescribing 
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low adherence to hydroxyurea27 as well as increased 
healthcare utilisation.28 29 Mental health training should 
be incorporated into all SCD- specific education. Addi-
tionally, there has been growing evidence to support the 
feasibility, acceptability and preliminary efficacy of digital 
health interventions in SCD.30 In particular, recent work 
in mobile health has demonstrated the feasibility of more 
innovative approaches to address the mental health needs 
in SCD.31 Moreover, there are ongoing efforts to leverage 
mobile health as an approach to optimise patients’ adher-
ence to hydroxyurea.32
The potential impact of hydroxyurea therapy remains 
diminished by underprescription and non- adherence. 
In this survey, providers reported reasons for initiation 
of treatment with hydroxyurea that are consistent with 
guidelines, with a higher frequency of disease compli-
cations (or higher disease severity) influencing the 
provider to offer this treatment. However, providers also 
reported that less than half of patients are treated with 
hydroxyurea, citing patient anticipation of side effects 
and concerns about adherence. Although hydroxyurea 
has not been linked to causing cancer,33 more than half 
of providers endorsed some level of importance to the 
perception of carcinogenesis as a deterrent to prescribing 
this medication.34 At the time of the survey, hydroxyurea 
prescribing may have been negatively influenced by the 
lack of US Food and Drug Adminstration (FDA) approval 
for use in children, a lack of formal guidelines for use in 
children, and concerns about medication effectiveness. 
With the recent FDA approval of hydroxyurea in chil-
dren, a major barrier has been removed. Dissemination 
of user- friendly, evidence- based guidelines is a logical 
next step to improve provider knowledge in prescribing 
hydroxyurea, potentially addressing the remaining 
barriers. Physicians indicated frequent consultation with 
other providers and external sources, highlighting the 
need for additional support mechanisms for non- SCD 
specialists who care for individuals with SCD. Ideally, 
hydroxyurea can be prescribed within a co- management 
model where the SCD specialist prescribes and adjusts 
dosing in combination with a primary care provider 
that could assist with lab value monitoring. However, 
providers across all specialty types and practice settings 
reported that they were unaware of the NHLBI primary 
care management guidelines and felt a clinical decision 
support tool would be useful for diagnosis, treatments, 
and avoiding complications. These guidelines may be of 
the most benefit to non- SCD specialty providers. This is 
currently being tested within the SCDIC in a prospective 
multicenter study utilizing implementation science to 
investigate the acceptability, perceived usefulness, and 
usability of a hydroxyurea toolbox for providers.35
Limitations
Although our study is one of the few to systematically 
survey the barriers to care in prescribing opioids and 
hydroxyurea (the two most prescribed medications 
in SCD) in different areas of the country, there were 
notable limitations. The convenience sampling of partic-
ipants recruited by various methods across sites might 
have introduced bias but could arguably have improved 
the generalisability of the responses across regions of the 
country. Providers who chose to participate may have 
different perspectives on SCD care than those who did 
not participate. Specifically, many providers may have 
been affiliated with the SCDIC study sites and, therefore, 
provide more evidence- based SCD care because of their 
affiliation with an SCD centre. This limitation would tend 
to underestimate the barriers and overestimate comfort 
level with prescribing hydroxyurea and opioids as well as 
treating acute and chronic pain. We were also unable to 
report a response rate due to our decision to increase the 
number of responses using anonymous data collection. 
Despite limitations, this is one of the largest surveys of 
non- emergency SCD providers conducted, and important 
barriers have been identified for further study.
CONCLUSIONS
Knowledge of the NHLBI guidelines for SCD among 
providers in the USA is low. Barriers to care among 
providers of patients with SCD exist and may be influ-
enced by providers’ specialty, prior training and practice 
setting. We have identified areas for improvement in pain 
management and hydroxyurea utilisation. Specifically, we 
found that perceptions of tolerance, addiction and depen-
dence influence providers’ comfort level in prescribing 
opioids and concerns about potential side effects and 
adherence are barriers to hydroxyurea utilisation. Addi-
tionally, we identified that improving mental health 
support for patients is an important need. Strategies to 
increase adoption of evidence- based guidelines should 
be tested to increase widespread use of best practices for 
individuals with SCD. In particular, future implementa-
tion studies are needed to improve provider knowledge 
and reduce misperceptions of therapies known to reduce 
or treat SCD complications and improve patients’ health 
outcomes.
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